NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Australian Patent & Trademark Office has accepted a new patent, No. 2004172022, “Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer,” and expects the patent to be formally issued in January, 2011. The patent protects among other things methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company’s lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy. This is the sixth patent in Pro-Pharmaceuticals growing patent portfolio that covers its core Galectin-targeting compounds and further reinforces the proprietary nature of DAVANAT®, the Company’s lead drug, in major markets around the world.
